Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3347131 | 0.92 | POLB (0.61) | TYMS | |
| SCHEMBL18589104 | 0.91 | POLB (0.59) | — | |
| SCHEMBL13970818 | 0.91 | POLB (0.59) | — | |
| SCHEMBL3345547 | 0.91 | POLB (0.59) | — | |
| SCHEMBL4267967 | 0.89 | TYMS (0.66) | TYMS | |
| SCHEMBL18597586 | 0.89 | TYMS (0.66) | TYMS | |
| SCHEMBL4277814 | 0.89 | TYMS (0.67) | TYMS | |
| SCHEMBL8694412 | 0.89 | TYMS (0.67) | TYMS | |
| SCHEMBL15115324 | 0.89 | TYMS (0.67) | TYMS | |
| SCHEMBL7269665 | 0.88 | TYMS (0.62) | TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190175756-A1 | METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE II WITH mRNA ENCODING ACID GLUCOSIDASE ALPHA (GAA) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175757-A1 | METHODS OF TREATING A SUBJECT HAVING FRIEDREICH'S ATAXIA WITH mRNA ENCODING FRATAXIN | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175758-A1 | METHODS OF TREATING A SUBJECT HAVING CITRULLINEMIA WITH mRNA ENCODING ARGININOSUCCINATE SYNTHASE (ASS) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175760-A1 | METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE WITH mRNA ENCODING GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT (G6PC) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175759-A1 | METHODS OF TREATING A SUBJECT HAVING PROPIONIC ACIDEMIA WITH mRNA ENCODING PROPIONYL-COA CARBOXYLASE, SUBUNIT ALPHA AND/OR BETA (PCCA AND/OR PCCB) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190167808-A1 | METHODS OF TREATING PHENYLKETONURIA WITH MRNA ENCODING PHENYLALANINE HYDROXYLASE (PAH) | CUREVAC AG (DE) | 2019-06-06 | — | — | US | claimed |
| US-20190167809-A1 | METHODS OF TREATING A SUBJECT WITH mRNA ENCODING COAGULATION FACTOR VIII (F8) | CUREVAC AG (DE) | 2019-06-06 | — | — | US | claimed |
| US-20180311379-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-11-01 | — | — | US | claimed |
| US-20180236102-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-08-23 | — | — | US | claimed |
| US-20180169267-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-06-21 | — | — | US | claimed |
| US-20170000858-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2017-01-05 | — | — | US | claimed |
| US-20160367704-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2016-12-22 | — | — | US | claimed |
| US-20160184406-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2016-06-30 | — | — | US | claimed |
| US-20100292135-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-18 | — | — | US | claimed |
| WO-2009127230-A1 | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION | CUREVAC GMBH (DE) | 2009-10-22 | — | — | WO | claimed |
| EP-1874801-A4 | INHIBITORS OF RECA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | UNIV NORTH CAROLINA (US) | 2009-03-25 | — | — | EP | claimed |
| EP-1874801-A2 | INHIBITORS OF RECA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | The University of North Carolina at Chapel Hill (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2006096757-A2 | INHIBITORS OF RECA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-09-14 | — | — | WO | claimed |
| US-20060199768-A1 | Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2006-09-07 | — | — | US | claimed |
| US-6288042-B1 | ADMINISTERING TO TREAT HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS | ARONEX PHARMACEUTICALS, INC. | 2001-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199768-A1 | Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens | RECQL, DNA2, WRN | TYMS 316/4885 |
| US-20100292135-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | RECQL, DNA2, WRN | TYMS 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.